Citations

Clear

127 citation(s) found for "Shari, G".

Abstract P2-13-09: Trajectories of fear of cancer recurrence in young breast cancer survivors
Schapira, Lidia , Gelber, Shari , Poorvu, Philip D. , Ruddy, Kathryn J. , Tamini, Rulla, Peppercorn, Jeffrey , Come, Steve, Rosenberg, Shoshana M. , Zheng, Yue , Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: P2-13-09-P2-13-09

10.1158/1538-7445.sabcs19-p2-13-09 Get It

Abstract Background: Fear of cancer recurrence (FCR) is prevalent among breast cancer survivors and more intense in younger women. Given that FCR is a powerful determinant of quality of life and is associated with healthcare utilization, identifying who may be at risk for experiencing elevated FCR without resolution can inform the timing and targeting of interventions. Methods: Participants included women diagnosed (dx’d) at age ≤40 enrolled in the Young Women’s Breast Cancer Study, a multi-site prospective cohort surveyed at baseline and regularly in follow-up. Surveys include the 3-item Lasry Fear of Recurrence Index which measures the degree of concern about recurrence and current health using 4-point Likert response options that provide a score ranging from 3-12; higher scores indicate greater concern. Group-based trajectory modeling was used to classify distinct FCR patterns from baseline (median of 5 months from dx) through 3 years post-dx. Multinomial logistic regression was used to identify the associated patient (socio-demographics and BRCA status), disease (stage, ER/PR/HER2) and treatment (surgery, chemotherapy) characteristics associated with each trajectory. Variables significant at p<0.05 in univariable models were entered into the final multivariable model. Results: 965 women with Stages 0-III breast cancer were included in the analysis, with a median age at dx of 37. Participants were predominantly non-Hispanic White (85%), partnered (76%) and had completed college (84%). There was a significant decrease in median FCR scores from baseline to year 3 (9 vs. 8, Wilcoxon signed-rank test P<0.01). Five FCR trajectories (Table) were identified: 1) 10.5% of participants reported low/stable FCR from baseline over follow-up; 2) 33.1% had moderate FCR that improved over time; 3) 5.5% had moderate FCR scores at baseline that worsened over time; 4) 30% had high FCR scores at baseline that improved over time; 5) 20.8% had high FCR at baseline that remained high at all time points. In the fully adjusted multinomial model, younger age at dx and Stage 3 and 2 (vs. 1) disease were associated with higher odds of being in the high/stable trajectory. Having a lumpectomy (vs. mastectomy) was associated with higher odds of being in a high/stable as well as moderate/improving trajectory while White (vs. non-White) women had higher odds of being in a trajectory of improving FCR. Receipt of chemotherapy and financial discomfort were significantly associated with assignment to specific FCR trajectories in univariate analyses, however did not remain significant in the adjusted model. Being partnered, BRCA mutation status, and ER/PR/HER2 status were not significantly associated with any FCR trajectory classification in univariate or multivariate analyses. Conclusion: While FCR improves over time for many young women with breast cancer, a substantial minority (26%) had FCR that was severe and did not improve or worsened over time. Younger women with higher stage disease who are at risk for high levels of unresolved FCR may benefit from intervention including early referral to mental health professionals. Ongoing monitoring of women at risk for developing FCR following active treatment is warranted. Table Mean FCR score for each trajectoryBaselineYear 1Year 2Year 3TrajectoriesLow/Stable (N=103)5.725.605.545.45Moderate/Improving (N=331)7.907.487.287.09Moderate/Worsening (N=34)6.748.329.6410.54High/Improving (N=294)9.889.419.088.67High/Stable (N=203)11.0211.0811.0310.88 Citation Format: Lidia Schapira, Yue Zheng, Shari Gelber, Philip Poorvu, Kathryn J Ruddy, Rulla Tamini, Jeffrey Peppercorn, Steve Come, Virginia Borges, Ann Partridge, Shoshana Rosenberg. Trajectories of fear of cancer recurrence in young breast cancer survivors [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-13-09.
Body weight changes in young breast cancer survivors and associated predictors.
Sella, Tal , Tan‐Wasielewski, Zhenying, Rosenberg, Shoshana M. , Poorvu, Philip D. , Ruddy, Kathryn J. , Gelber, Shari , Schapira, Lidia , Come, Steven E. , Peppercorn, Jeffrey , Ligibel, Jennifer A. , Tamimi, Rulla M. , Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 37 | Issue: 15_suppl | Pages: 11574-11574

10.1200/jco.2019.37.15_suppl.11574 Get It

11574 Background: Weight gain after cancer diagnosis is common in cancer survivors and has been linked to increased treatment toxicity, poor quality of life, and increased risk of second cancers and overall mortality. Young breast cancer (BC) survivors may be especially susceptible to weight changes given the impact of treatments such as chemotherapy and hormonal therapy on menopausal status. Methods: We identified women with Stage 0-III breast cancer diagnosed at ≤40 years (y) between 2006-2016 from a multi-center prospective cohort study. Clinical data including self-reported pre-diagnosis and follow-up weights were obtained using baseline and follow-up patient surveys. Participants missing baseline weight, pregnant at diagnosis/within 1y of diagnosis or with BC recurrence within 1y were excluded; those pregnant or with BC recurrence between 1-3y from diagnosis were excluded from the 3y analysis. Menopausal status at baseline and treatment-related amenorrhea (TRA) in follow-up were defined by self-reported last menstrual period. Factors associated with weight gain (>5%) were evaluated using univariate two-sided Fisher's exact test. Results: At baseline, 1y and 3y post diagnosis, 956, 899 and 687 women were eligible for analysis respectively. Median age at diagnosis was 37y (17 - 40), 65% received endocrine therapy and 74% chemotherapy. Premenopausal status was verified in 94% at baseline. Mean BMI at baseline was 24.4 (SD 5.3) kg/m2; 20% (187/956) were overweight and 12% (116/956) obese. At 1y and 3y, mean BMI increased modestly to 24.7 (SD 5.6) and 24.9 (SD 5.2), respectively with weight gain (>5%) observed in 18% (164/899) and 13% (87/687) respectively. 37% (300/804) and 32% (196/615) of eligible premenopausal subjects experienced TRA at 1y and 3y, respectively. Receipt of chemotherapy, receipt of endocrine therapy and TRA were not associated with weight gain at any timepoint. Conclusions: In this large prospective cohort of young BC survivors, mean BMI increased only modestly over time. Self-reported weight gain was not associated with treatment and not exacerbated by TRA. Further analysis to understand the effects of physical activity and other predictors of weight gain in this population are ongoing.
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
Poorvu, Philip D. , Gelber, Shari , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Collins, Laura C. , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Russell, Christy , Tamimi, Rulla M. , Borges, Virginia F. , Warner, Ellen , Jakubowski, Debbie , Winer, Eric P. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | December 6, 2019 | Volume: 38 | Issue: 7 | Pages: 725-733

10.1200/jco.19.01959 | PMID 31809240 Get It

PURPOSE The 21-gene recurrence score (RS) assay is prognostic among women with early-stage estrogen receptor–positive (ER+) and human epidermal growth factor receptor 2–negative (HER2−) breast cancer and is used to inform recommendations for chemotherapy. Women ≤ 40 years of age represent a minority of patients studied using gene expression profiles. METHODS The Young Women's Breast Cancer Study is a prospective cohort of women diagnosed with breast cancer at age ≤ 40 years and enrolled patients between 2006 and 2016 (N = 1,302). We identified patients with stage I-III ER+/HER2− breast cancer. The RS assay was performed on banked specimens for patients who had not been tested clinically. Distant recurrence-free survival (DRFS) was assessed by TAILORx and traditional RS risk groups among patients with axillary node–negative (N0) and limited node–positive (N1) breast cancer. RESULTS Among eligible women (N = 577), 189 (33%) had undergone RS testing, and 320 (56%) had banked specimens sufficient for testing. Median follow-up was 6.0 years. Median age at diagnosis was 37.2 years; 300 of 509 patients (59%) had N0 breast cancer, of whom 195 (65%) had an RS of 11-25 and fewer than half (86 of 195; 44%) received chemotherapy. Six-year DRFS rates were 94.4% and 92.3% (RS < 11), 96.9% and 85.2% (RS 11-25), and 85.1% and 71.3% (RS ≥ 26) among women with N0 and N1 disease, respectively. CONCLUSION The RS assay is prognostic among young women with node-negative and limited node-positive breast cancer, representing a valuable tool for risk stratification. Disease outcomes with a median follow-up of 6 years among young women with N0 disease and an RS of 0-25, a minority of whom received chemotherapy, and node-positive disease with an RS < 11 were very good, whereas those with N0 disease and an RS ≥ 26 or N1 disease with an RS ≥ 11 experienced substantial risk of early distant recurrence.
Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Abu‐Rustum, Nadeem R. , Yashar, Catheryn M. , Bean, Sarah , Bradley, Kristin , Campos, Susana M. , Chon, Hye Sook, Damast, Shari , Dorigo, Oliver , Eifel, Patricia J. , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Han, Ernest , Huh, Warner K. , Lurain, John R., Mariani, Andrea , Nagel, Christa , Nekhlyudov, Larissa , Fader, Amanda N. , Remmenga, Steven W., Reynolds, R. Kevin, Sisodia, Rachel, Tillmanns, Todd , Ueda, Stefanie , Wyse, Emily , McMillian, Nicole R., Scavone, Jillian L., Chu, Christina , Cohn, David E. , Crispens, Marta Ann , Mutch, David G.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 7, 2019 | Volume: 17 | Issue: 11 | Pages: 1374-1391

10.6004/jnccn.2019.0053 | PMID 31693991 Get It

Gestational trophoblastic neoplasia (GTN), a subset of gestational trophoblastic disease (GTD), occurs when tumors develop in the cells that would normally form the placenta during pregnancy. The NCCN Guidelines for Gestational Trophoblastic Neoplasia provides treatment recommendations for various types of GTD including hydatidiform mole, persistent post-molar GTN, low-risk GTN, high-risk GTN, and intermediate trophoblastic tumor.
Identification of novel, immune-mediating extracellular vesicles in human lymphatic effluent draining primary cutaneous melanoma
Maus, Rachel L.G., Jakub, James W. , Nevala, Wendy K. , Christensen, Trace , Sutor, Shari L., Flotte, Thomas J. , Christensen, Trace A, Jakub, James W , Hieken, Tina J. , Markovic, Svetomir N.

Mayo Clinic

OncoImmunology | September 30, 2019 | Volume: 8 | Issue: 12 | Pages: No page available

10.1080/2162402x.2019.1667742 | PMID 31741769 Get It

P008  Improving efficiency with a nurse driven immunomodulator lab monitoring tracking tool
Shari, Frueh, Ashley, Grinhaug, Kati, Cavanaugh, Patricia, Winzenburg, Desiree, Tynsky

Mayo Clinic

American Journal of Gastroenterology | July 21, 2019 | Volume: 114 | Issue: 1 | Pages: S3-S3

10.14309/01.ajg.0000578104.80739.a1 Get It

BACKGROUND: Immunomodulator medications are commonly used in the care of patients with inflammatory bowel disease (IBD). American College of Gastroenterology's and American Gastroenterology Association's IBD practice guidelines recommend routine lab monitoring during initiation of and ongoing medication therapy to avoid the risk of acute or delayed bone marrow suppression and/or liver toxicity. Within the IBD clinic at a large academic medical center, registered nurses (RNs) routinely monitor lab results of patients enrolled in a lab monitoring program. Lab results were previously monitored using an institutionally created guideline and messaging system within an electronic health record (EHR) that was being discontinued. The messaging tool was suboptimal and limited the RNs ability to view the total volume of patients in the lab monitoring program. Additionally, there was no efficient way to view lab due dates, differentiate internal vs external lab collection expectations, track patient's compliance with lab monitoring requirements, nor efficient tracking of patients requiring more frequent monitoring due to abnormal test results. Subsequently, these inefficiencies made it difficult for nurse leaders to assess the nursing workload associated with the coordination of care for these patients. AIM: The primary endpoint was to develop electronic tools specifically designed for immunomodulator lab monitoring, which would assist with RN efficiency in tracking a large volume of patients enrolled in the required lab monitoring. METHODS: Input was obtained by benchmarking with similar nursing workflows involving patients requiring close monitoring; and brainstorming with the RN team regarding essential elements to place within the report. Informatics colleagues assisted in the design and development of the electronic tools. RESULTS: Development of an immunomodulator-specific electronic tracking tool that is integrated into the new EHR. The closer tracking of patient adherence improves quality and safety for patients taking these medications. The new tool allows convenient access to the following information (was not previously available): Volume of patients enrolled, Due dates for required lab tests (delinquent or next expected result), Quick links to view lab results, At-a-glance way to see which patients are high priority for next lab results, Stratifying options to track patient enrollment by provider, specific drug prescribed, medication start date, internal/external lab location, pending enrollments and more. Additional outcomes included: Written standardized RN workflows, Defined RN training program and written reference guides, Adapting the standardized IBD tool for use within the hepatitis C and Hepatobiliary practices, Quantifiable data available for future analysis related to nursing workload. CONCLUSION: Development of a comprehensive EHR-integrated lab monitoring tool allows an IBD practice to more efficiently track patient adherence, which in turn improves quality and safety for patients taking these medications. Additionally, the report tool is an initial step toward better quantification of the nursing workload associated with the ongoing care coordination required with this patient population.
Diagnostic and treatment delays in young women with breast cancer.
Poorvu, Philip D. , Sella, Tal , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Gelber, Shari , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Zheng, Yue , Tamimi, Rulla M. , Borges, Virginia F. , Warner, Ellen , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 6575-6575

10.1200/jco.2019.37.15_suppl.6575 Get It

6575 Background: Delays in diagnosis (dx) and treatment (tx) affect breast cancer (BC) outcomes. We sought to identify factors associated with delays among young women, who do not undergo routine screening and often have pregnancy or breastfeeding-related breast changes that may mask a BC. Methods: The Young Women’s Breast Cancer Study is a multicenter, prospective cohort that enrolled 1302 women with newly dx BC age ≤40 between 2006-2016. Women reported the method and timing of cancer detection on the baseline survey. 231 were ineligible or excluded due to missing information. Among those reporting self-detected cancers, using multivariable regression we evaluated factors associated with delays ≥90 days (d) from symptom to presentation (self delay) and presentation to dx (care delay); in stage 0-III BC we evaluated delays ≥60d from dx to tx (tx delay). Results: 1071 eligible women had median age at dx of 37 yrs (17-40) and 74% reported self-detected cancers. Self delay or care delay ≥90d was reported in 17% and 13%, respectively. Factors inversely associated with self delay included pregnancy at dx (vs nulliparous, OR 0.10, CI 0.01-0.78) and perceived financial comfort (vs not, OR 0.62, CI 0.41-0.93). Women dx ≤1 year post-partum who breastfed (vs nulliparous, OR 2.60, CI 1.14-5.93) and those with a family history of breast/ovarian cancer (vs none, OR 1.79, CI 1.00-3.19) were more likely to have a care delay. Age was inversely associated with care delays (OR 0.94, CI 0.89-0.99). Tx delay was reported by 10% (105/1015), and associated with being single (vs partnered, OR 1.61, CI 1.02-2.56 ), non-white (vs white, OR 1.85, CI 1.09-3.13) and having Stage 0 BC (vs stage 1, OR: 3.08, CI 1.65-5.77); women with stage 3 BC (vs stage 1, OR 0.13, CI 0.03-0.56) were less likely to have a tx delay. Conclusions: In this cohort, most young women with BC underwent timely dx and tx initiation. Women dx ≤1 year post-partum who breastfed were more likely to experience a care delay, likely because lactational changes may mask BC signs and symptoms. The associations of perceived financial status with self delay and non-white race with tx delay underscore the need for additional support to ensure timely care for underserved populations with the goal of eliminating disparities in outcomes.
Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer
Wassermann, Johanna , Gelber, Shari , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Schapira, Lidia , Come, Steven E. , Meyer, Meghan E., Partridge, Ann H. , Partridge, Ann H , Tamimi, Rulla M. , Borges, Virginia F.

Mayo Clinic

Cancer | May 23, 2019 | Volume: 125 | Issue: 18 | Pages: 3266-3274

10.1002/cncr.32192 | PMID 31120571 Get It

Background Young age is a known factor associated with suboptimal adherence to endocrine therapy (ET) for adjuvant breast cancer (BC) treatment. This study was aimed at assessing nonadherent behaviors and associated factors among young women with early‐stage hormone receptor–positive BC. Methods As part of a multicenter, prospective cohort of women with a diagnosis of BC at or under the age of 40 years, participants were surveyed 30 months after their diagnosis about adherent behaviors. Among those who reported taking ET, adherence was measured with a 3‐item Likert‐type scale: Do you ever forget to take your ET? If you feel worse when you take your ET, do you stop taking it? Did you take your ET exactly as directed by your doctor over the last 3 months? Women reporting at least 1 nonadherent behavior were classified as nonadherers. Variables with a P value <.20 were included in a multivariable logistic model. Results Among 384 women, 194 (51%) were classified as nonadherers. Univariate factors that retained significance in the multivariable model included educational level (odds ratio [OR], 0.50 for high vs low; P = .04), level of social support according to the Medical Outcome Study Social Support Survey (OR, 0.98 per 1 point; P = .01), and confidence with the decision regarding ET measured on a 0 to 10 numerical scale (OR, 0.63 for high vs low; P = .04). Conclusions Findings from this study could help to identify young patients at higher risk for nonadherence. Interventions adapted to the level of education and aimed at reinforcing support and patients' confidence in their decision to take ET could improve adherence and associated outcomes in this population.
Treatment-related amenorrhea among young women one year following diagnosis of early-stage breast cancer.
Poorvu, Philip D. , Gelber, Shari , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Come, Steven E. , Schapira, Lidia , Tamimi, Rulla M. , Bober, Sharon L. , Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 9523-9523

10.1200/jco.2015.33.15_suppl.9523 Get It